ABSTRACT

Introduction: The etiology of pleural effusion may vary depending on the geographic location or temporality. In Mexico, the information available regarding pleural effusion derives from third-level reference centers specialized in respiratory diseases. Possibly the results do not reflect the prevalence of this condition in other scenarios, such as, general wards. Objective: To determine the etiology, clinical manifestations and differences of the pleural fluid analysis between several etiologies of pleural effusion in a general reference center in the southeast of Mexico. Material and methods: An observational, prospective study that includes all consecutive cases with pleural effusion admitted in a period of 3 years. On admission, a diagnostic thoracentesis was performed and detailed clinical history was obtained. Results: We included 178 cases that were admitted with pleural effusion. The leading cause was parapneumonic (34%). Among symptoms, dyspnea was the most frequent (91%) and was not different among several pleural effusion etiologies (p = 0.095). Among symptoms, systemic manifestations such as hyporexia, weight loss were more prevalent in malignant pleuraleffusions and tuberculosis; meanwhile, fever, bronchial manifestations (cough, expectoration) and chest pain were more frequent in cases of infectious etiology (parapneumonic and tuberculosis). Conclusions: Parapneumonic effusions was the most prevalent cause of pleural effusion in a general reference hospital. Dyspnea was the main symptom among several etiologies without statistical difference. The data contrast with previously published reports, possibly due to differences in the hospital´s care system.

KEYWORDS

Epidemiology, etiology, pleural effusion, thoracentesis, parapneumonic, cancer.

REFERENCES

1. Feller-Kopman D, Light R. Pleural disease. N Engl J Med 2018;378(8):740-751. doi: 10.1056/NEJMra1403503.

2. Porcel JM, Light RW. Pleural effusions. Dis Mon 2013;59(2):29-57. doi: 10.1016/j.disamonth.2012.11.002.

3. Hooper C, Lee YC, Maskell N; Group BTSPleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65 Suppl 2:ii4-17. doi: 10.1136/thx.2010.136978.

4. McGrath EE, Anderson PB. Diagnosis of pleural effusion: a systematic approach. Am J Crit Care 2011;20(2):119-127. doi: 10.4037/ajcc2011685.

5. Light RW, Macgregor MI, Luchsinger PC, Ball WC, Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972;77(4):507-513.

6. Light RW. The Light criteria: the beginning and why they are useful 40 years later. Clin Chest Med 2013;34(1):21-26. doi: 10.1016/j.ccm.2012.11.006.

7. Maldonado F, Lentz RJ, Light RW. Diagnostic approach to pleural diseases: new tricks for an old trade. F1000Res 2017;6:1135. doi: 10.12688/f1000research.11646.1.

8. Light RW. Pleural effusions. Med Clin North Am 2011;95(6):1055-1070. doi: 10.1016/j.mcna.2011.08.005.

9. Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses.Arch Bronconeumol 2014;50(5):161-165. doi: 10.1016/j.arbres.2013.11.007.

10. Sosa-Juárez A, García-Sancho C, Sánchez-Hernández JD, et al. Epidemiología del derrame pleural en el INER, 2011-2012. Neumol Cir Torax 2013;72(2):136-141.

11. Mejía-Olivares B, Valdez-López HG, Martínez-Delgado IA, et al. Etiología y prevalencia del derrame pleural en la UMAE No. 34 Monterrey, Nuevo León, México.Neumol Cir Torax 2013;72(1):20-24.

12. Riis P. Thirty years of bioethics: the Helsinki Declaration 1964-2003. New Rev Bioeth 2003;1(1):15-25.

13. Bhatnagar R, Maskell NA. Treatment of complicated pleural effusions in 2013. Clin Chest Med 2013;34(1):47-62. doi: 10.1016/j.ccm.2012.11.004.

14. Villena V, López Encuentra A, Echave-Sustaeta J, Alvarez Martínez C, Maríin Escribano P. [Prospective study of 1,000 consecutive patients with pleural effusion. Etiology of the effusion and characteristics of the patients]. Arch Bronconeumol 2002;38(1):21-26.

15. Walker SP, Morley AJ, Stadon L, et al. Nonmalignant pleural effusions: a prospective study of 356 consecutive unselected patients. Chest 2017;151(5):1099-1105.doi: 10.1016/j.chest.2016.12.014.

16. Bintcliffe OJ, Lee GY, Rahman NM, Maskell NA. The management of benign non-infective pleural effusions. Eur Respir Rev 2016;25(141):303-316.doi: 10.1183/16000617.0026-2016.

17. Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology 2015;20(4):654-659.doi: 10.1111/resp.12496. 

18. Bibby AC, Dorn P, Psallidas I, et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J 2018;52(1): pii: 1800349. doi: 10.1183/13993003.00349-2018.

19. Bielsa S, Valencia H, Ruiz-González A, Esquerda A, Porcel JM. Serum C-reactive protein as an adjunct for identifying complicated parapneumonic effusions. Lung 2014;192(4):577-581.doi: 10.1007/s00408-014-9606-5.

20. Porcel JM, Bielsa S, Esquerda A, Ruiz-González A, Falguera M. Pleural fluid C-reactive protein contributes to the diagnosis and assessment of severity of parapneumonic effusions. Eur J Intern Med 2012;23(5):447-450. doi: 10.1016/j.ejim.2012.03.002.

21. Vega-Sánchez AE, Che-Morales JL, Vargas-Mendoza GK, Manjarrez-Martín DA, Cortés-Telles A. Procalcitonina sérica como biomarcador diagnóstico de derrame paraneumónico o empiema. Neumol Cir Torax 2017;76(1):7-13.

22. Sahn SA, Light RW. The sun should never set on a parapneumonic effusion. Chest 1989;95(5):945-947.

23. Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 2013;158(11):825-830.doi: 10.7326/0003-4819-158-11-201306040-00007.

24. Davies HE, Davies RJ, Davies CW; Group BTSPleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65 Suppl 2:ii41-53. doi: 10.1136/thx.2010.137000.